Evidence map›Paper›PMID 41451514›Full record

Trial reportJournal of psychopharmacology (Oxford, England)2026

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.

Kurt Stocker, Matthias Hartmann, Yasmin Schmid, Severin B Vogt, Anna M Becker, Laura Ley, Isabelle Straumann, Denis Arikci, Aaron Klaiber, Livio Erne and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of psychopharmacology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07479550 (A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07479550 phase2not yet recruitingnot on this map

A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder

TypeinterventionalSponsorStanford UniversityRan2026 to 2027Enrolled10ConditionsMajor DepressionArmsPsilocybin (Usona Institute), Propofol, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review.Clinical pharmacology and therapeutics · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kurt StockerPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0000-0002-6161-7114
Matthias HartmannFaculty of Psychology, UniDistance Suisse, Brig, Switzerland.ORCID 0000-0003-1132-1339
Yasmin SchmidPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0000-0002-3618-584X
Severin B VogtPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0009-0007-3650-3549
Anna M BeckerPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0000-0001-5308-7945
Laura LeyPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0009-0003-9881-4693
Isabelle StraumannPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0009-0008-2952-586X
Denis ArikciPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0009-0006-6763-021X
Aaron KlaiberPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0009-0004-5199-7004
Livio ErnePsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0009-0001-6260-7663
Patrick VizeliPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0000-0002-5954-4446
Friederike HolzePsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0000-0003-3143-1519
Matthias E LiechtiPsychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland.ORCID 0000-0002-1765-9659

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the 3D-ASC remains widely used for summarizing broader experiential domains.

aimsWe wanted to provide an updated, psychometrically revalidated version of the ASC. We tested whether the 42-item 11-ASC could be integrated into a coherent three-dimensional framework. We further hypothesized that this revised model would outperform the original 66-item 3D-ASC while preserving its conceptual clarity.

methodsData from 901 5D-ASC questionnaires from 398 healthy participants across 16 randomized, mostly placebo-controlled psychedelic (lysergic acid diethylamide, psilocybin, mescaline, and

resultsTen of the 11 subscales formed three higher-order dimensions-Positive (PosE), Distressing (DisE), and Perceptual (PerE) effects-mirroring the 3D-ASC but with improved fit. We propose this as the 3D-ASCr scale. The Anxiety subscale could not be integrated due to consistent floor effects (low anxiety in the sample), but given its clinical relevance, it is retained within 3D-ASCr (as part of DisE or a standalone subscale).

conclusionThe 3D-ASCr is an updated version of the ASC and is recommended for use with classic serotonergic psychedelics in both clinical practice and research.

Indexed as

ConsciousnessHallucinogensAdultFemaleHumansLysergic Acid DiethylamideMaleMescalineMiddle AgedPsilocybinPsychometricsReproducibility of ResultsSurveys and QuestionnairesYoung AdultHallucinogensLysergic Acid DiethylamideMescalinePsilocybinDMTLSDmescalinepsilocybinpsychedelics

Identifiers

PMID41451514
PMCPMC13310268

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.